Ameriprise
NMRA icon

Ameriprise’s Neumora Therapeutics NMRA Stock Holding History

Ameriprise’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-117,504
Closed -$214K – 4173
2025
Q3 		$214K Buy
+117,504
New +$190K ﹤0.01% 3891
2025
Q2 		– Sell
-11,107
Closed -$11.1K – 4077
2025
Q1 		$11.1K Sell
11,107
-107,567
-91% -$184K ﹤0.01% 3999
2024
Q4 		$1.26M Buy
+118,674
New +$1.42M ﹤0.01% 3137

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return

Ameriprise's NMRA Position: Q4 2025 in Review

Ameriprise sold out of Neumora Therapeutics (NMRA) in Q4 2025, closing a stake of 117,504 shares — an estimated $214K sold.

Ameriprise first reported a position in NMRA in Q4 2024 and held it in 3 quarters. The position peaked at $1.26M in Q4 2024. 102 funds tracked by Wall St. Rank hold NMRA as of Q4 2025.

  • Ameriprise reported no remaining Neumora Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 117,504 Neumora Therapeutics shares in Q4 2025, an estimated $214K.
  • Ameriprise first reported a position in Neumora Therapeutics in Q4 2024 and held it in 3 quarters.
  • Ameriprise's Neumora Therapeutics position peaked at $1.26M in Q4 2024.
  • 102 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.